Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.
Take a look through the key trials investigating BCG/ICI combinations in BCG-naïve NMIBC. In BCG-naïve non–muscle invasive bladder cancer (NMIBC), emerging options are largely focused on combining BCG ...
The Virtuoso Surgical Robotic System received FDA breakthrough designation for bladder lesion removal, enabling expedited development and review processes. En bloc resection improves cancer staging ...
A major focus of the discussion is the integration of advanced prostate cancer therapeutics into urology offices. In this episode of Pearls and Perspectives, Amy Pearlman, MD, speaks with Vahan ...
Ensuring consistent diagnostic quality remains critical. In this video, Veeru Kasivisvanathan, MBBS, BSc, FRCS, MSc, PGCert, PhD, discussed findings from the PRIME trial, a multicenter international ...
Several experts share their thoughts on the impact of the gemcitabine intravesical system for BCG-unresponsive NMIBC. On September 9, 2025, the FDA approved the gemcitabine intravesical system ...
BioTraceIO360 received FDA 510(k) clearance for kidney ablation, expanding its previous liver tumor ablation indication. The platform standardizes minimally invasive care, enhancing treatment planning ...
Stephen J. Freedland, MD, placed dietary guidance within the broader context of survivorship care. In discussing the links between diet and prostate cancer, Stephen J. Freedland, MD, a professor of ...
The FDA approved subcutaneous pembrolizumab and berahyaluronidase alfa-pmph for solid tumors in patients 12 years or older. Recommended dosages are 395 mg/4800 U every 3 weeks or 790 mg/9600 U every 6 ...
Inlexzo provides extended local delivery of gemcitabine, achieving an 82% complete response rate in BCG-unresponsive NMIBC with CIS. The SunRISe-1 trial demonstrated durable responses, with over 50% ...
Sunobinop showed significant symptom improvement in 41% of IC/BPS patients versus 9% with placebo, indicating its potential efficacy. The investigational compound targets the NOP receptor, affecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback